Leef Brands (LEEEF) Cash & Equivalents (2024 - 2026)

Leef Brands (LEEEF) posted Cash & Equivalents of $5.8 million for Q1 2026, up 162.74% sequentially from $2.2 million in Q4 2025.

Leef Brands (LEEEF) Cash & Equivalents (2024 - 2026) Analysis & Trends

Leef Brands has reported Cash & Equivalents for 3 years, with the latest figure at $5.8 million in Q1 2026.

Quarterly Cash & Equivalents changed N/A year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (changed N/A YoY) and the FY2025 annual result came in at $2.2 million, down 19.81% from the prior year.
Cash & Equivalents advanced to $5.8 million in Q1 2026 per LEEEF's latest filing, from $2.2 million in the prior quarter.
Over five years, Cash & Equivalents peaked at $5.8 million in Q1 2026 and troughed at $2.2 million in Q4 2025.
A 3-year average of $3.6 million and a median of $2.7 million in 2024 frame the typical range for Cash & Equivalents.
The widest YoY moves for Cash & Equivalents: up 19.81% in 2025, down 19.81% in 2025.
Over 3 years, Cash & Equivalents stood at $2.7 million in 2024, then dropped by 19.81% to $2.2 million in 2025, then jumped by 162.74% to $5.8 million in 2026.
According to Business Quant data, Cash & Equivalents over the past three periods registered $5.8 million, $2.2 million, and $2.7 million for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash & Equiv. (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	1.11 Bn
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	3.66 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	1.48 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	2.89 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	1.80 Bn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	886.50 Mn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	332.40 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	530.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	164.00 Mn
10	Leef Brands	59.45 Mn	54.50 Mn	2.41 Mn	4.95 Mn

Download Data